4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Shares Sold by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC trimmed its position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) by 13.1% during the 3rd quarter, Holdings Channel.com reports. The fund owned 41,399 shares of the company’s stock after selling 6,253 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in 4D Molecular Therapeutics were worth $448,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. nVerses Capital LLC purchased a new stake in shares of 4D Molecular Therapeutics in the 3rd quarter valued at $40,000. Values First Advisors Inc. acquired a new position in 4D Molecular Therapeutics during the third quarter valued at $57,000. China Universal Asset Management Co. Ltd. boosted its holdings in 4D Molecular Therapeutics by 64.6% in the third quarter. China Universal Asset Management Co. Ltd. now owns 9,995 shares of the company’s stock valued at $108,000 after purchasing an additional 3,922 shares during the last quarter. Proficio Capital Partners LLC acquired a new stake in 4D Molecular Therapeutics during the 3rd quarter worth about $108,000. Finally, Quest Partners LLC raised its stake in shares of 4D Molecular Therapeutics by 17,409.1% during the 2nd quarter. Quest Partners LLC now owns 5,778 shares of the company’s stock valued at $121,000 after buying an additional 5,745 shares during the last quarter. Hedge funds and other institutional investors own 99.27% of the company’s stock.

4D Molecular Therapeutics Stock Performance

Shares of 4D Molecular Therapeutics stock opened at $6.31 on Friday. The business’s 50 day moving average price is $7.79 and its 200 day moving average price is $13.98. The company has a market cap of $291.70 million, a price-to-earnings ratio of -2.21 and a beta of 2.74. 4D Molecular Therapeutics, Inc. has a one year low of $5.58 and a one year high of $36.25.

Analyst Upgrades and Downgrades

FDMT has been the topic of a number of recent research reports. Morgan Stanley assumed coverage on 4D Molecular Therapeutics in a research note on Thursday, November 21st. They issued an “underweight” rating and a $8.00 target price on the stock. Royal Bank of Canada dropped their target price on 4D Molecular Therapeutics from $40.00 to $39.00 and set an “outperform” rating on the stock in a research report on Thursday, November 14th. Chardan Capital reaffirmed a “buy” rating and issued a $39.00 price target on shares of 4D Molecular Therapeutics in a report on Thursday, November 14th. Leerink Partners reissued an “outperform” rating and issued a $36.00 price objective (down from $40.00) on shares of 4D Molecular Therapeutics in a report on Thursday, September 19th. Finally, Bank of America cut their price objective on 4D Molecular Therapeutics from $79.00 to $46.00 and set a “buy” rating for the company in a research report on Wednesday. One analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have issued a buy rating to the stock. Based on data from MarketBeat.com, 4D Molecular Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $42.56.

4D Molecular Therapeutics Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.